Premium
The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consecutive patients with advanced disease
Author(s) -
B. Sørensen Jens,
Hirsch Fred R.,
Olsen Jens
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880715)62:2<361::aid-cncr2820620222>3.0.co;2-m
Subject(s) - medicine , adenocarcinoma , subtyping , papillary adenocarcinoma , carcinoma , lung cancer , lung , stage (stratigraphy) , pathology , adenocarcinoma of the lung , respiratory disease , cancer , gastroenterology , oncology , paleontology , computer science , biology , programming language
The prognostic impact of subtyping pretreatment histologic material in adenocarcinoma of the lung (ACL) according to WHO was evaluated in 259 consecutive, inoperable, Stage III patients. One hundred thirty patients (50%) had acinar adenocarcinoma, 23 (9%) had papillary adenocarcinoma, 13 (5%) had bronchioloalveolar carcinoma, and 32 (12%) had solid carcinoma with mucus formation; five patients (2%) had other types of lung cancer. Subtyping was impossible due to cytology or insufficient histologic material in 56 patients (22%). Bronchioloalveolar carcinoma had the longest median duration of response to chemotherapy (47 weeks), time to progression (33 weeks), and median survival (40 weeks). Corresponding values for solid carcinoma with mucus formation were 8, 12, and 22 weeks. Acinar and papillary adenocarcinoma were intermediate. Survival curves and response rates were similar ( P > 0.05). Bronchioloalveolar carcinoma had 46% 1‐year survivors compared to 16% to 22% for other subtypes. The subtypes may have an impact on the prognosis of ACL, but further evaluation is required.